|
1
|
Zhuang Y, Jiang H, Li H, Dai J, Liu Y, Li
Y, Miao L, Cai H, Xiao Y, Xia H, et al: Down-regulation of long
non-coding RNA AFAP1-AS1 inhibits tumor cell growth and invasion in
lung adenocarcinoma. Am J Transl Res. 9:2997–3005. 2017.PubMed/NCBI
|
|
2
|
Herbst RS, Morgensztern D and Boshoff C:
The biology and management of non-small cell lung cancer. Nature.
553:446–454. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Morgensztern D, Ng SH, Gao F and Govindan
R: Trends in stage distribution for patients with non-small cell
lung cancer: A national cancer database survey. J Thorac Oncol.
5:29–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xu G, Chen J, Pan Q, Huang K, Pan J, Zhang
W, Chen J, Yu F, Zhou T and Wang Y: Long noncoding RNA expression
profiles of lung adenocarcinoma ascertained by microarray analysis.
PLoS One. 9:e1040442014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Li M, Ning J, Li Z, Fei Q, Zhao C, Ge Y
and Wang L: Long noncoding RNA OIP5-AS1 promotes the progression of
oral squamous cell carcinoma via regulating miR-338-3p/NRP1 axis.
Biomed Pharmacother. 118:1092592019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Y, Shi F, Xia Y and Zhao H: LncRNA
OIP5-AS1 predicts poor prognosis and regulates cell proliferation
and apoptosis in bladder cancer. J Cell Biochem. 2018.(Online ahead
of print).
|
|
8
|
Zhang J, Zhao T, Tian L and Li Y: LncRNA
OIP5-AS1 promotes the proliferation of hemangioma vascular
endothelial cells via regulating miR-195-5p/NOB1 axis. Front
Pharmacol. 10:4492019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deng J, Deng H, Liu C, Liang Y and Wang S:
Long non-coding RNA OIP5-AS1 functions as an oncogene in lung
adenocarcinoma through targeting miR-448/Bcl-2. Biomed
Pharmacother. 98:102–110. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang M, Sun X, Yang Y and Jiao W: Long
non-coding RNA OIP5-AS1 promotes proliferation of lung cancer cells
and leads to poor prognosis by targeting miR-378a-3p. Thorac
Cancer. 9:939–949. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Acunzo M, Romano G, Wernicke D and Croce
CM: MicroRNA and cancer-a brief overview. Adv Biol Regul. 57:1–9.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yao Y, Ma J, Xue Y, Wang P, Li Z, Liu J,
Chen L, Xi Z, Teng H, Wang Z, et al: Knockdown of long non-coding
RNA XIST exerts tumor-suppressive functions in human glioblastoma
stem cells by up-regulating miR-152. Cancer Lett. 359:75–86. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun Y and Qin B: Long noncoding RNA MALAT1
regulates HDAC4-mediated proliferation and apoptosis via decoying
of miR-140-5p in osteosarcoma cells. Cancer Med. 7:4584–4597. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhou W, Wang X, Yin D, Xue L, Ma Z, Wang
Z, Zhang Q, Zhao Z, Wang H, Sun Y and Yang Y: Effect of miR-140-5p
on the regulation of proliferation and apoptosis in NSCLC and its
underlying mechanism. Exp Ther Med. 18:1350–1356. 2019.PubMed/NCBI
|
|
15
|
Shi SL and Zhang ZH: Long non-coding RNA
SNHG1 contributes to cisplatin resistance in non-small cell lung
cancer by regulating miR-140-5p/Wnt/β-catenin pathway. Neoplasma.
66:756–765. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang P, Xiong J, Zuo L, Liu K and Zhang H:
miR1405p regulates cell migration and invasion of nonsmall cell
lung cancer cells through targeting VEGFA. Mol Med Rep.
18:2866–2872. 2018.PubMed/NCBI
|
|
17
|
Witt O, Deubzer HE, Milde T and Oehme I:
HDAC family: What are the cancer relevant targets? Cancer Lett.
277:8–21. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jensen ED, Schroeder TM, Bailey J,
Gopalakrishnan R and Westendorf JJ: Histone deacetylase 7
associates with Runx2 and represses its activity during osteoblast
maturation in a deacetylation-independent manner. J Bone Miner Res.
23:361–372. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kato H, Tamamizu-Kato S and Shibasaki F:
Histone deacetylase 7 associates with hypoxia-inducible factor
1alpha and increases transcriptional activity. J Biol Chem.
279:41966–41974. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li B, Samanta A, Song X, Iacono KT, Bembas
K, Tao R, Basu S, Riley JL, Hancock WW, Shen Y, et al: FOXP3
interactions with histone acetyltransferase and class II histone
deacetylases are required for repression. Proc Natl Acad Sci USA.
104:4571–4576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Caslini C, Hong S, Ban YJ, Chen XS and
Ince TA: HDAC7 regulates histone 3 lysine 27 acetylation and
transcriptional activity at super-enhancer-associated genes in
breast cancer stem cells. Oncogene. 38:6599–6614. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wei Y, Zhou F, Zhou H, Huang J, Yu D and
Wu G: Endothelial progenitor cells contribute to neovascularization
of non-small cell lung cancer via histone deacetylase 7-mediated
cytoskeleton regulation and angiogenic genes transcription. Int J
Cancer. 143:657–667. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lei H, Gao Y and Xu X: LncRNA TUG1
influences papillary thyroid cancer cell proliferation, migration
and EMT formation through targeting miR-145. Acta Biochim Biophys
Sin (Shanghai). 49:588–597. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu Y, Shen HM, Fang DM, Meng QJ and Xin
YH: LncRNA HCP5 promotes the development of cervical cancer by
regulating MACC1 via suppression of microRNA-15a. Eur Rev Med
Pharmacol Sci. 22:4812–4819. 2018.PubMed/NCBI
|
|
26
|
Yao N, Yu L, Zhu B, Gan HY and Guo BQ:
LncRNA GIHCG promotes development of ovarian cancer by regulating
microRNA-429. Eur Rev Med Pharmacol Sci. 22:8127–8134.
2018.PubMed/NCBI
|
|
27
|
Gobillot TA, Humes D, Sharma A, Kikawa C
and Overbaugh J: The robust restriction of zika virus by type-I
interferon in A549 cells varies by viral lineage and is not
determined by IFITM3. Viruses. 12:5032020. View Article : Google Scholar
|
|
28
|
Massa D, Baran M, Bengoechea JA and Bowie
AG: PYHIN1 regulates pro-inflammatory cytokine induction rather
than innate immune DNA sensing in airway epithelial cells. J Biol
Chem. 295:4438–4450. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng
H, Qian X, Bi J and Lin Y: ACE2 inhibits breast cancer angiogenesis
via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer
Res. 38:1732019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo J, Chen M, Ai G, Mao W, Li H and Zhou
J: Hsa_circ_0023404 enhances cervical cancer metastasis and
chemoresistance through VEGFA and autophagy signaling by sponging
miR-5047. Biomed Pharmacother. 115:1089572019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duma N, Santana-Davila R and Molina JR:
Non-small cell lung cancer: Epidemiology, screening, diagnosis, and
treatment. Mayo Clin Proc. 94:1623–1640. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Schiller JH, Harrington D, Belani CP,
Langer C, Sandler A, Krook J, Zhu J and Johnson DH; Eastern
Cooperative Oncology, : Comparison of four chemotherapy regimens
for advanced non-small-cell lung cancer. N Engl J Med. 346:92–98.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kumarakulasinghe NB, van Zanwijk N and Soo
RA: Molecular targeted therapy in the treatment of advanced stage
non-small cell lung cancer (NSCLC). Respirology. 20:370–378. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cao MX, Jiang YP, Tang YL and Liang XH:
The crosstalk between lncRNA and microRNA in cancer metastasis:
Orchestrating the epithelial-mesenchymal plasticity. Oncotarget.
8:12472–12483. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li SJ, Wu YX, Liang YH, Gao Y, Wu AB,
Zheng HY and Yang ZX: LncRNA HANR aggravates the progression of
non-small cell lung cancer via mediating miRNA-140-5p. Eur Rev Med
Pharmacol Sci. 24:704–711. 2020.PubMed/NCBI
|
|
36
|
Dressel U, Bailey PJ, Wang SC, Downes M,
Evans RM and Muscat GE: A dynamic role for HDAC7 in MEF2-mediated
muscle differentiation. J Biol Chem. 276:17007–17013. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ma C and D'Mello SR: Neuroprotection by
histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun
expression through a deacetylase-independent mechanism. J Biol
Chem. 286:4819–4828. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Saharinen P, Eklund L, Pulkki K, Bono P
and Alitalo K: VEGF and angiopoietin signaling in tumor
angiogenesis and metastasis. Trends Mol Med. 17:347–362. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xu H, Zhang Y, Pena MM, Pirisi L and Creek
KE: Six1 promotes colorectal cancer growth and metastasis by
stimulating angiogenesis and recruiting tumor-associated
macrophages. Carcinogenesis. 38:281–292. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu H, Chen Y, Li Y, Li C, Qin T, Bai M,
Zhang Z, Jia R, Su Y and Wang C: miR195 suppresses metastasis and
angiogenesis of squamous cell lung cancer by inhibiting the
expression of VEGF. Mol Med Rep. 20:2625–2632. 2019.PubMed/NCBI
|
|
41
|
Sinha S, Khan S, Shukla S, Lakra AD, Kumar
S, Das G, Maurya R and Meeran SM: Cucurbitacin B inhibits breast
cancer metastasis and angiogenesis through VEGF-mediated
suppression of FAK/MMP-9 signaling axis. Int J Biochem Cell Biol.
77:41–56. 2016. View Article : Google Scholar : PubMed/NCBI
|
